Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

NICE recommends guselkumab as psoriasis treatment option

NICE has issued final draft guidance that recommends guselkumab (Tremfya, Janssen) as a treatment option for adults who have severe plaque psoriasis.

NICE has issued final draft guidance that recommends guselkumab (Tremfya, Janssen) as a treatment option for adults who have severe plaque psoriasis. The recommendation applies to people who have not responded to, or cannot take, other systemic therapies including ciclosporin and methotrexate. Treatment should be stopped at 16 weeks if the psoriasis has not responded adequately. Evidence showed that guselkumab is likely to provide similar health benefits at a similar or lower cost to two other biological drugs previously recommended by NICE, ixekizumab and secukinumab. Clinical trial results also showed that guselkumab is more effective than recommended TNF-alpha inhibitors (adalimumab,

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy